news
Fibril ‘fuzzy coats’ boost Parkinson’s protein spread
New research reveals that the flexible ‘fuzzy coat’ surrounding α-synuclein fibrils plays a critical role in how Parkinson’s disease spreads between brain cells.
List view / Grid view
Parkinson's disease (PD)
article
Advanced drug development for neurodegenerative diseases with α-synuclein
Discover how α-synuclein tests are transforming the diagnosis and treatment of neurodegenerative diseases, offering hope for earlier detection, better-targeted therapies and faster drug development.
article
Landmark study aims to detect Parkinson’s before symptoms
Grifols' Chronos-PD initiative leverages its extensive plasma repository to identify early biomarkers of Parkinson's disease, advancing early detection and contributing to the development of innovative therapies.
news
The Michael J Fox Foundation for Parkinson’s Research awards grant to Grifols for pioneering study
Grifols has received a $21 million grant from The Michael J. Fox Foundation to fund a pioneering study aimed at identifying early biomarkers for Parkinson's disease (PD).
news
Carbonic anhydrase inhibitors protect against tau protein build-up
The glaucoma drug methazolamide removed tau build-up and lessened signs of dementia in genetically-engineered zebrafish and mice.
news
Specific HERV expression signatures linked to MS and ALS
The study identified which specific HERVs are important in increasing susceptibility for neurodegenerative diseases.
news
Mechanism that controls reactivation of neural stem cells discovered
New insights into the role of SUMOylation in the brain could lead to new targeted therapies for neurodegenerative conditions.
news
New link found between immune system and neurological disease
Findings show that alpha-synuclein and an immune response are required for Lewy body formation, in an effect specific to dopaminergic neurons.
article
Drug candidates with blockbuster potential for CNS diseases
In this Q&A, Kristina Torfgård, CEO of IRLAB Therapeutics, discusses the Company’s current drug development pipeline, including two promising preclinical projects. Kristina also details their proprietary drug discovery and development platform which has enabled the production of many first-in-class candidates, and what she envisions for the future.
article
A novel class of drug candidates for neurodegenerative diseases
At AAIC 2024, AC Immune unveiled a new class of antibody drug conjugates, called morADC (Morphomer® antibody drug conjugate). In this Q&A, CEO of AC Immune, Andrea Pfeifer, discusses how morADC uses the capabilities of the company’s two discovery platforms to combine two highly selective molecules, resulting in drug candidates…
news
New model offers a unique method to study Parkinson’s disease
Mice with rod-specific VPS35 deletion demonstrate a pathology more similar to human Parkinson’s disease, compared to other mouse models.
news
Modelling the blood-brain barrier with organoids
The world’s first generation of human BBB organoids from hPSCs accurately replicated features of cerebral cavernous malformation.
news
Improved method to control the generation of dopaminergic neurons
A synthetic antibody selectively activates the Wnt signalling pathway and directs stem cells to differentiate into neurons.
news
Evaluating the anti-obesity effects of tocotrienols
The new study found T3s treatment exhibited neuroprotective effects in HFSD-fed mice by mitigating oxidative stress.
article
Investigating antipsychotics in a Parkinson’s disease psychosis model
In this Q&A, Dr Nicholas Waters, Head of R&D at IRLAB, shares how three compounds, including IRLABs Mesdopetam and an experimental dopamine D3 receptor antagonist, could reverse features associated with the psychosis-like state of Parkinson’s disease.
